A Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty

C. Colwell, M. Froimson, M. Mont, M. Ritter, R. Trousdale, K. Buehler, A. Spitzer, T. Donaldson, D. Padgett.
The Journal of Bone and Joint Surgery, Feb 2014, 05;96(3):177-183

Read lead article http://jbjs.org/content/96/3/177

Read the commentary written on the article http://jbjs.org/content/96/3/e23.full-text.pdf+html

Findings:  Use of the mobile compression device with or without aspirin for patients undergoing arthroplasty of a lower-extremity joint provides a noninferior risk for the development of venous thromboembolism compared with current pharmacological protocols.

Learn more about this study

What did the study compare?
VTE prevention using ActiveCare®+S.F.T compared to pharmacological protocols (anticoagulants)

How was the study designed?
Registry study in which the use of the ActiveCare® +SFT device was studied for a minimum of 10 days (during admission and later at home). VTE rates were compared with published symptomatic rates for pharmacological protocols (anticoagulants)

How were the study results tested?
Patients with clinical suspicion of DVT underwent duplex ultrasonography of both legs. Patients with clinical suspicion of PE were evaluated with spiral CT of the lungs. All patients were clinically evaluated three months after surgery documenting whether there was any evidence that a DVT or PE event had occurred postoperatively.

Results:

Of 3060 patients, 28 (0.92%) had VTE (23 distal DVT, 3 proximal DVT, and 5- PE).

Conclusions:
When compared to current pharmacologic protocols, including enoxaparin, rivaroxaban, warfarin, fondaparinux and dabigatran,  the use of ActiveCare® +SFT as monotherapy for patients undergoing primary total joint arthroplasty is as efficient in VTE prevention.